로딩 중…
지수 로딩 중…
Summit Therapeutics Inc.
SMMT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$13.04+0.19%
2026-08-03
Financials
Valuation Metrics
Summit Therapeutics Inc.'s Market Cap is $10.13B. At end of 2025 it was $13.08B. Ranked #935 of 3,111 in US market (top 30%), #299 of 1,445 on NASDAQ (top 21%), #45 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.13B | US#935/3,111 Sec#45/269 |
| Revenue | $0.00 | US#2,980/3,111 Sec#205/269 |
| Net Income | $-856M | US—/3,111 Sec—/269 |
| Total Assets | $752M | US#2,573/3,111 Sec#116/269 |
| Net Assets | $630M | US#2,097/3,111 Sec#91/269 |
| Value | ||
| P/B | 16.07x | US#2,763/3,111 Sec#222/269 |
| FCF Yield | -4.02% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -135.89% | US#2,887/3,111 Sec#230/269 |
| Financial Health | ||
| Debt Ratio | 19.40% | US#220/3,111 Sec#80/269 |
| Total Debt | $20M | US#2,726/3,111 Sec#182/269 |
| FCF | $-407M | US#2,825/3,111 Sec#253/269 |
| Cash | $419M | US#1,200/3,111 Sec#69/269 |
| Current Ratio | 6.96x | US#339/3,111 Sec#113/269 |
| Performance | ||
| 1Y Return | -51.81% | US#2,966/3,111 Sec#245/269 |
| 1M Return | -15.40% | US#2,452/3,111 Sec#179/269 |
| From 52W High | -57.89% | US#2,882/3,111 Sec#236/269 |
| 1Y MDD | -57.20% | US#2,656/3,111 Sec#207/269 |
| Trading | ||
| Volume | 3,378,561 shares | US#482/3,111 Sec#33/269 |
| Trading Value | $44M | US#1,299/3,111 Sec#81/269 |
| Per Share | ||
| EPS | $-1.44 | US—/3,111 Sec—/269 |
| BPS | $0.88 | US#2,643/3,111 Sec#208/269 |